Tru-D SmartUVC will join members of Premier at the Premier Annual Breakthroughs Conference and Exhibition in Nashville, Tennessee, June 19-22, 2018. Tru-D invites attendees to visit its booth #147 to learn about its cutting-edge technology that was recently proven to reduce C. diff and other multidrug-resistant organisms (MRDOs) hospital-wide. Premier

Oneida Health Systems invested in Tru-D in 2016 to help drive its already low infection rates further down. Before implementing Tru-D, along with other infection prevention protocols, the facility’s C. diff rate was .61; by 2017, it dropped significantly to .18—a 70% decrease. “Though actual cost savings from HAI avoidance

By Alice Brewer, MPH, CIC, Director of Clinical Affairs for Tru-D SmartUVC A new study proves that enhanced terminal room disinfection with Tru-D SmartUVC leads to a decrease in risk of acquisition of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide. The study, Effectiveness of

Tru-D SmartUVC, a leader in the UVC disinfection industry, will attend and exhibit at APIC 2018, June 13-15 in Minneapolis, MN, sharing ground-breaking infection prevention data. Each year, APIC delivers the largest annual conference of infection preventionists from across the U.S., and Tru-D invites the more than 2,500 attendees to

A new study proves that enhanced terminal room disinfection with Tru-D SmartUVC leads to a decrease in risk of acquisition of targeted multidrug-resistant organisms such as C. diff and VRE for all patients, hospital-wide. The study, Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant